1,2-Dimethyl-1 H-[4,4']bipyrimidinyl-6-one | 1083006-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,2-Dimethyl-1 H-[4,4']bipyrimidinyl-6-one
• 英文别名: 1,2-dimethyl-1H-[4,4']bipyrimidinyl-6-one；1,2-Dimethyl-1H-[4,4]bipyrimidinyl-6-one；2,3-dimethyl-6-pyrimidin-4-ylpyrimidin-4-one
• CAS: 1083006-39-6
• 化学式: C₁₀H₁₀N₄O
• 分子量: 202.216
• InChiKey: BKMZMPXHKGMZPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,2-Dimethyl-1 H-[4,4']bipyrimidinyl-6-one 在 氰基磷酸二乙酯 、 硫酸 、 双氧水 、 碘 、 三乙胺 、 肼 作用下， 以 四氯化碳 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 2-Methoxy-N-(1-methyl-6-oxo-1,6-dihydro-[4,4']bipyrimidinyl-2-ylmethyl)-nicotinamide
  参考文献：
  名称：

  EP1992621

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氧代-3-(嘧啶-4-基)-丙酸乙酯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.25h， 生成 1,2-Dimethyl-1 H-[4,4']bipyrimidinyl-6-one
  参考文献：
  名称：

  EP1992620

  摘要：

  公开号：

文献信息

• [EN] 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-[1,4] OXAZÉPANE-4-PYRIMIDONE
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2010114179A1

  公开（公告）日：2010-10-07

  A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C-F or the like; R1 represents a C1-C3 alkyl group; Y represents oxygen atom or N-R7; R2, R3, R4, R5, R6 and R7 each independently represents hydrogen atom, a C1-C6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I）或其药学上可接受的盐：其中Z代表氮原子，C-F或类似物；R1代表C1-C3烷基基团；Y代表氧原子或N-R7；R2、R3、R4、R5、R6和R7分别独立地代表氢原子，C1-C6烷基基团，或由化学式（II）表示的基团：该化合物用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。
• ARYLAMIDE PYRIMIDONE DERIVATIVES
  申请人：CHEREZE Nathalie

  公开号：US20100087460A1

  公开（公告）日：2010-04-08

  The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本发明公开了一系列由式（I）表示的嘧啶酮衍生物或其盐、溶剂或水合物：其中X、Z、R1、R2、R3、R4、R5、R6、R7、n和m的定义如本文所述。本文还公开了制备式（I）化合物、其中间体及其在治疗多种疾病条件中的用途的方法。
• INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF
  申请人：Furuya Rikizou

  公开号：US20120059165A1

  公开（公告）日：2012-03-08

  A production method of an optically active 2-4-(5-substituted-oxadiazolyl) phenyl}morpholine which is useful as an intermediate for synthesizing a pharmaceutical agent is provided and the method comprises the following steps 1) to 4): 1) reacting a bromophenylmorpholine with a hexacyanoferrate(II) or a hydrate thereof at a temperature of from 110° C. to 140° C. in a reaction mixture comprising a Na 2 CO 3 , an organophosphorus compound, and a palladium catalyst in a polar aprotic solvent alone or combination of a polar aprotic solvent and other polar aprotic solvent or hydrocarbon solvent to give a cyanophenylmorpholine; 2) reacting the cyanophenylmorpholine with hydroxylamine or hydroxylamine hydrochloride at a temperature of from 10° C. to 40° C. in an aprotic polar solvent to give a hydroxylamine derivative; 3) reacting the hydroxylamine derivative with an acylation reagent selected from the group consisting of aliphatic acyl halides, aromatic acyl halides, aliphatic acyl anhydrides and aromatic anhydrides; and 4) keeping the mixture obtained after step 3) at a temperature of from 60° C. to 140° C. to give a 2-4-(5-substituted-oxadiazolyl) phenyl}morpholine.

  提供了一种制备光学活性的2-4-(5-取代-噁唑基)苯基}吗啡啶的生产方法，该方法可用作合成药物的中间体，包括以下步骤1）至4）：1）在极性无水溶剂或极性无水溶剂和其他极性无水溶剂或碳氢溶剂的反应混合物中，以110℃至140℃的温度，使用Na2CO3、有机磷化合物和钯催化剂，将溴苯基吗啡与六氰合铁(II)或其水合物反应，得到氰苯基吗啡；2）在无水极性溶剂中，以10℃至40℃的温度，将氰苯基吗啡与羟胺或羟胺盐酸盐反应，得到羟胺衍生物；3）将羟胺衍生物与选自脂肪族酰卤、芳香族酰卤、脂肪族酰酐和芳香族酰酐的酰化试剂反应；4）将步骤3）得到的混合物保持在60℃至140℃的温度下，得到2-4-(5-取代-噁唑基)苯基}吗啡啶。
• 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES
  申请人：Watanabe Kazutoshi

  公开号：US20120095216A1

  公开（公告）日：2012-04-19

  A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C—F or the like; R 1 represents a C 1 -C 3 alkyl group; Y represents oxygen atom or N—R 7 ; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents hydrogen atom, a C 1 -C 6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I）或其药学上可接受的盐，用于治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（如阿尔茨海默病）。其中，Z代表氮原子、C—F或类似物；R1代表C1-C3烷基；Y代表氧原子或N—R7；R2、R3、R4、R5、R6和R7各自独立地代表氢原子、C1-C6烷基或由式（II）表示的基团。
• Arylamide pyrimidone derivatives
  申请人：Chereze Nathalie

  公开号：US08592436B2

  公开（公告）日：2013-11-26

  The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本发明公开了一系列由式（I）或其盐、溶剂或水合物表示的嘧啶酮衍生物：其中X、Z、R1、R2、R3、R4、R5、R6、R7、n和m的定义如本文所述。本文还公开了制备式（I）化合物、其中间体及其在治疗各种疾病条件中的用途的方法。